BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16042684)

  • 1. Immunotherapy in multiple myeloma--possibility or probability?
    Harrison SJ; Cook G
    Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of multiple myeloma: the start of a long and tortuous journey.
    Harrison SJ; Cook G; Nibbs RJ; Prince HM
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1769-85. PubMed ID: 17181491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current role of immunotherapy in multiple myeloma.
    Hájek R; Adam Z; Krivanová A; Doubek M; Korístek Z; Vorlícek J
    Acta Med Austriaca; 1998; 25(3):79-85. PubMed ID: 9816399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular immunotherapy for multiple myeloma.
    Rosenblatt J; Avigan D
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DC in multiple myeloma immunotherapy.
    Turtle CJ; Brown RD; Joshua DE; Hart DN
    Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.
    Klammer M; Roddie PH
    Expert Rev Vaccines; 2006 Apr; 5(2):211-22. PubMed ID: 16608421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q
    Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
    Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
    Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
    Blair A; Goulden NJ; Libri NA; Oakhill A; Pamphilon DH
    Blood Rev; 2005 Nov; 19(6):289-300. PubMed ID: 16275419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunodeficiency and immunotherapy in multiple myeloma.
    Pratt G; Goodyear O; Moss P
    Br J Haematol; 2007 Sep; 138(5):563-79. PubMed ID: 17686051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Less yin, more yang: confronting the barriers to cancer immunotherapy.
    Lizée G; Cantu MA; Hwu P
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5250-5. PubMed ID: 17875752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma.
    Gorschlüter M; Ziske C; Glasmacher A; Schmidt-Wolf IG
    Clin Cancer Res; 2001 Aug; 7(8):2195-204. PubMed ID: 11489792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
    Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma.
    Vari F; Munster DJ; Hsu JL; Rossetti TR; Mahler SM; Gray PP; Turtle CJ; Prue RL; Hart DN
    Br J Haematol; 2008 Nov; 143(3):374-7. PubMed ID: 18729856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-mediated and cellular immunotherapy in multiple myeloma.
    Ritchie DS; Quach H; Fielding K; Neeson P
    Immunotherapy; 2010 Mar; 2(2):243-55. PubMed ID: 20635931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immunotherapy in multiple myeloma.
    Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
    Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.